GreenRoc Accelerates their World Class Project to Production as Early as 2028. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksYGEN.L Regulatory News (YGEN)

  • There is currently no data for YGEN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Statement

21 Jan 2010 07:00

RNS Number : 8912F
ViaLogy PLC
21 January 2010
 



VIALOGY PLC

TRADING STATEMENT

 

PERMIAN BASIN WELL SUCCESS IS TECHNOLOGY MILESTONE

--- "A-Level" stress test for QuantumRD

--- Broad oil patch application seen for technology

London, January 21, 2010, ViaLogy PLC (LSE: VIY). ViaLogy announces that, under contract to its client Fasken Oil and Ranch, Ltd. of Midland, Texas, the first successful well has been drilled and is in the process of being completed on their Andrews County prospect. The leading privately-held Exploration and Production company agreed to collaborate with ViaLogy to use its proprietary technology, QuantumRD®, to analyze 3-D and multi-component seismic data, well logs and geological records to locate well sites in a 10 square mile Permian Basin acreage block. 

Drilling at the ViaLogy-designated location took three weeks and reached a prescribed total depth of 11,241 feet. Initial well log analysis shows potential for multiple zones that could be high-graded, highlighted by a net interval of over 50' feet of significant porosity in the Strawn formation alone. Strawn limestone porosities are typically very low. For this formation to be economically viable porosity must reach at least 4%. One of ViaLogy's key challenges was to locate this porosity and to quantify its aerial extent. Strawn targets are typically found at depths greater than 9000 feet and with 3% porosities or less are deemed non-productive. The QuantumRD technology succeeded in locating large continuous zones of 6% plus porosity, a major achievement. Detailed volumetrics will be computed in the near-term.

 

All the more significant is the fact that over the last 50 years only three of 18 attempted Strawn wells in the prospect area showed production. Of the 15 remaining, seven were completed to produce oil from shallower zones in the Wolfcamp formations, no porosity having been found in the Strawn. Eight were declared as dry holes. Additionally, preliminary work shows that the ViaLogy technology can increase the ability to detect hydrocarbon presence directly using seismic data to accurately characterize Wolfcamp carbonates.

 

Participating in the Fasken prospect analysis as an advisor is Dr. Bob Hardage of the University of Texas' Bureau of Economic Geology (UT BEG), widely acknowledged as one of America's leading technology centers for hydrocarbon exploration.

 

Reviewing the drilling results, Dr. Hardage commented, "The prediction of a higher porosity zone within the Strawn is impressive and appears to validate the advantages of the weak signal processing capability underlying QuantumRD to see subtle changes in the data. Porosity variations in Strawn stratigraphy are difficult to amplify using conventional geophysical processing." Despite advances in 3D seismic acquisition and processing, the exploration industry has faced a major challenge in characterizing porosity in complex stratigraphic formations known to exhibit fracture and structural changes below acquisition resolution.

 

According to the client firm's Chief Geophysicist, "We are impressed by the accuracy of ViaLogy's predictions, and especially pleased with QuantumRD's capability to use seismic data to accurately detect porosity zones within the Strawn formation. This was a very difficult problem. Significant undeveloped acreage still exists in the Midland Basin. The introduction of a technology that can characterize porosity in deeper carbonate intervals could make a substantial difference."

He added, "This well demonstrated to us QuantumRD's potential to determine drilling locations based on our exploration criteria. We look forward to working closely with ViaLogy to discover and develop deeper formations on our acreage including the Strawn, Devonian, and Ellenburger"

ViaLogy CEO Robert Dean said, "We couldn't be more pleased with our performance. The only real test for an oil-finding technology is: Can it find oil in the field - not in the laboratory? This is what we are focused on and we're looking forward to proving our technology in the field. Our core patented technology, a technique for the injection of noise to enhance the signal to noise ratios seen in seismic data, allows us to extract more information from the data - and to identify sub-surface characteristics more effectively than other techniques. This challenge was to locate oil and gas in formations that had often eluded other efforts and available techniques. This has been a great partnership that will allow us to enhance and improve the ability of E&P companies to produce from Wolfberry, Strawn and deeper formations."

ViaLogy PLC

Robert W Dean, President & CEO - US +1 626-296-6337 (mobile: +1 703-589-3807) 

Terry Bond, Chairman - UK & Europe +44 (0) 1235-834734 (mobile: 07860 842756) 

Nominated Advisor to ViaLogy PLC (Seymour Pierce) 

Mark Percy +44 (0) 20-7107-8000 

About ViaLogy: Network Centric Signal Processing 

ViaLogy is a leading innovator of network-centric, real-time signal processing platforms for sensor applications. ViaLogy is currently deploying and designing computational systems, powered by its patented technologies, for applications in life sciences, public safety and security, surveillance, defense and geoseismology. ViaLogy focuses on market driven problems where automation, timeliness, quality and reliability of information processing are essential. ViaLogy's core competency incorporates rapidly and accurately detecting weak signals buried in high noise background and clutter. This technology can be employed to solve problems involving sensor integration and information overload challenges involving video, telephony and control sensors, as well as for enhancement of numerous signal processing applications. For more information, visit our website at www.ViaLogy.com

Except for statements of historical fact, the information presented herein constitutes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results,

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTPGUUUGUPUPPU
Date   Source Headline
14th Dec 20217:00 amRNSHalf-year Report
6th Dec 20217:00 amRNSNotice of Half-year results
18th Nov 20217:00 amRNSDPYD screening recommended in Spain
28th Oct 20217:00 amRNSRanger® Technology to be presented at Labroots
26th Oct 20217:00 amRNSHalf-year Trading update
29th Sep 20217:00 amRNSResult of AGM
28th Sep 20213:00 pmRNSAGM update
28th Sep 20217:00 amRNSAGM Statement
15th Sep 20217:00 amRNSShare option awards
1st Sep 20217:00 amRNSISO 15189:2012 accreditation received
1st Sep 20217:00 amRNSNotice of AGM and Annual Report 2021
19th Aug 202112:04 pmRNSCOVID-19 Surge testing contract
11th Aug 20217:01 amRNSEarn-out Milestone, Issue of Equity & TVR
11th Aug 20217:00 amRNSAudited Final results&unaudited Q1 business update
6th Aug 20217:00 amRNSConfirmation of Results Date
23rd Jul 20217:00 amRNSNotice of Results
1st Jul 202111:09 amRNSHolding(s) in Company
21st Jun 20217:00 amRNSSecond Strategic Partner for Coastal Genomics
18th Jun 20217:00 amRNSContract Award: DPYD testing kits for NHS Wales
17th Jun 20214:32 pmRNSExercise of Options
9th Jun 20217:00 amRNSMulti-year licence and supply agreement
21st May 20214:30 pmRNSDirector/PDMR Shareholding
19th May 20217:00 amRNSDistribution Partnership
18th May 20217:00 amRNSLaunch of IONA Care NIPT service offering
17th May 20217:00 amRNSFurther testing service agreement for MHC
29th Apr 20217:00 amRNSFull year Trading update
26th Apr 20217:00 amRNSFurther National Microbiology Framework awards
19th Apr 20211:21 pmRNSFurther National Microbiology Framework contract
19th Apr 20217:00 amRNSNational Framework contract award
12th Apr 20217:00 amRNSEarn-out Milestone, Issue of Equity & TVR
6th Apr 20212:43 pmRNSTesting service agreement with MyHealthCheckedplc
6th Apr 20211:54 pmRNSAgreement with Boots for COVID-19 sample kits
29th Mar 20214:00 pmRNSCOVID-19 update
23rd Mar 20217:00 amRNSShare option exercises and awards
19th Mar 20217:00 amRNSTwin Pregnancy study published using IONA® Test
17th Mar 20217:00 amRNSAppointment of VP of Sales North America
11th Mar 20217:00 amRNSYourgene Genomic Services portfolio expansion
1st Mar 20217:00 amRNSFirst US Supply Agreement
22nd Feb 20217:00 amRNSPartnership with NPH
10th Feb 202110:51 amRNSCorrection: Director / PDMR Shareholding
10th Feb 20217:00 amRNSDirector/PDMR Shareholding
8th Feb 20217:00 amRNSTrading update
13th Jan 20217:00 amRNSDPYD screening recommended in Belgium
11th Jan 20217:00 amRNSClarigene® SARS-CoV-2 Product Update
8th Jan 20217:00 amRNSIssue of Share Options
24th Dec 20207:00 amRNSCOVID-19 update
17th Dec 20207:00 amRNSHalf-year Report
15th Dec 20207:00 amRNSNotice of Half-year Results
2nd Dec 20207:00 amRNSDPYD kits recommended by NHS England
2nd Dec 20207:00 amRNSGenomic testing service launch and Change of name

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.